R.a. Session II - 10 Nov 2022 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
Director, 10%+ Owner
Signature
/s/ Kamran Alam, Attorney-in-Fact
Issuer symbol
TSHA
Transactions as of
10 Nov 2022
Net transactions value
$0
Form type
4
Filing time
23 Dec 2022, 15:15:43 UTC
Previous filing
25 Feb 2022
Next filing
08 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Employee Stock Option (right to buy) Award $0 +199,500 $0.000000 199,500 10 Nov 2022 Common Stock 199,500 $1.95 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Reporting Person's annual incentive compensation for 2021 performance awarded in the discretion of the compensation committee of the Issuer's board of directors on November 10, 2022.
F2 25% of the total number of shares underlying the option shall vest and become exercisable on November 10, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.